Related Experiment Videos
Platelet monoamine oxidase response to lithium treatment in psychiatric patients
Abstract:
Platelet monoamine oxidase (MAO) activity was studied in bipolar and schizophrenic patients treated with lithium and was found to be increased as a nonspecific drug effect. Greater MAO increase in manic patients was correlated with lesser clinical improvement. There was no correlation of MAO activity with short-term outcome in schizophrenic patients. Change in MAO was not correlated with lithium dosage or plasma levels. Patients with baseline MAO values below the median had the largest activity increases. Platelet MAO might thus be characterized as a state variable, increased by lithium as a nonspecific pharmacologic effect, with the increase associated with poor clinical outcome in manic patients.
Insights
Lithium treatment non-specifically increases platelet monoamine oxidase (MAO) activity in bipolar and schizophrenic patients. This increase is linked to poorer clinical outcomes in manic patients, suggesting MAO activity is a state variable.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Platelet monoamine oxidase (MAO) is an enzyme involved in neurotransmitter metabolism.
- Lithium is a mood stabilizer commonly used in treating bipolar disorder and schizophrenia.
- The effect of lithium on MAO activity in psychiatric patients requires further elucidation.
Purpose of the Study:
- To investigate the impact of lithium treatment on platelet monoamine oxidase (MAO) activity in patients with bipolar disorder and schizophrenia.
- To explore the correlation between changes in MAO activity and clinical outcomes in these patient groups.
Main Methods:
- Platelet MAO activity was measured in bipolar and schizophrenic patients undergoing lithium treatment.
- Correlations were analyzed between MAO activity changes, clinical improvement, lithium dosage, and plasma levels.
- Baseline MAO values were compared with activity increases.
Main Results:
- Lithium administration resulted in a nonspecific increase in platelet MAO activity across both patient groups.
- A greater increase in MAO activity in manic patients correlated with diminished clinical improvement.
- No significant correlation was observed between MAO activity and short-term outcomes in schizophrenic patients.
- Changes in MAO activity did not correlate with lithium dosage or plasma concentrations.
- Patients with lower baseline MAO activity exhibited the most substantial increases.
Conclusions:
- Platelet MAO activity appears to be a state variable, influenced by lithium therapy.
- The observed increase in MAO activity is a nonspecific pharmacologic effect of lithium.
- Elevated MAO activity following lithium treatment is associated with poorer clinical outcomes in manic patients.